Signs and symptoms of multiple sclerosis (English Wikipedia)

Kurtzke JF (November 1983). "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)". Neurology. 33 (11): 1444–1452. doi:10.1212/WNL.33.11.1444. PMID 6685237.
Jongen PJ (June 2006). "Psychiatric onset of multiple sclerosis". Journal of the Neurological Sciences. 245 (1–2): 59–62. doi:10.1016/j.jns.2005.09.014. PMID 16631798. S2CID 33098365.
Paty D, Studney D, Redekop K, Lublin F (1994). "MS COSTAR: a computerized patient record adapted for clinical research purposes". Annals of Neurology. 36 (Suppl): S134 – S135. doi:10.1002/ana.410360732. PMID 8017875. S2CID 23425667.
Moore H, Nair KP, Baster K, Middleton R, Paling D, Sharrack B (August 2022). "Fatigue in multiple sclerosis: A UK MS-register based study". Multiple Sclerosis and Related Disorders. 64: 103954. doi:10.1016/j.msard.2022.103954. PMID 35716477.
Hubbard AL, Golla H, Lausberg H (June 2021). "What's in a name? That which we call Multiple Sclerosis Fatigue". Multiple Sclerosis. 27 (7): 983–988. doi:10.1177/1352458520941481. PMC 8142120. PMID 32672087.
Bakalidou D, Giannopapas V, Giannopoulos S (July 2023). "Thoughts on Fatigue in Multiple Sclerosis Patients". Cureus. 15 (7): e42146. doi:10.7759/cureus.42146. PMC 10438195. PMID 37602098.
Tervonen T, Fox RJ, Brooks A, Sidorenko T, Boyanova N, Levitan B, et al. (2023). "Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment". Multiple Sclerosis Journal: Experimental, Translational and Clinical. 9 (1): 20552173221150370. doi:10.1177/20552173221150370. PMC 9880588. PMID 36714174.
Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, et al. (June 2019). "Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 90 (6): 642–651. doi:10.1136/jnnp-2018-320050. PMC 6581095. PMID 30683707.
Ellison PM, Goodall S, Kennedy N, Dawes H, Clark A, Pomeroy V, et al. (September 2022). "Neurostructural and Neurophysiological Correlates of Multiple Sclerosis Physical Fatigue: Systematic Review and Meta-Analysis of Cross-Sectional Studies". Neuropsychology Review. 32 (3): 506–519. doi:10.1007/s11065-021-09508-1. PMC 9381450. PMID 33961198.
Newland P, Starkweather A, Sorenson M (July 2016). "Central fatigue in multiple sclerosis: a review of the literature". The Journal of Spinal Cord Medicine. 39 (4): 386–399. doi:10.1080/10790268.2016.1168587. PMC 5102292. PMID 27146427.
Chen MH, Wylie GR, Sandroff BM, Dacosta-Aguayo R, DeLuca J, Genova HM (August 2020). "Neural mechanisms underlying state mental fatigue in multiple sclerosis: a pilot study". Journal of Neurology. 267 (8): 2372–2382. doi:10.1007/s00415-020-09853-w. PMID 32350648.
Christogianni A, O'Garro J, Bibb R, Filtness A, Filingeri D (November 2022). "Heat and cold sensitivity in multiple sclerosis: A patient-centred perspective on triggers, symptoms, and thermal resilience practices". Multiple Sclerosis and Related Disorders. 67: 104075. doi:10.1016/j.msard.2022.104075. PMID 35963205.
Davis SL, Wilson TE, White AT, Frohman EM (November 2010). "Thermoregulation in multiple sclerosis". Journal of Applied Physiology. 109 (5): 1531–1537. doi:10.1152/japplphysiol.00460.2010. PMC 2980380. PMID 20671034.
Sumowski JF, Leavitt VM (July 2014). "Body temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure". Archives of Physical Medicine and Rehabilitation. 95 (7): 1298–1302. doi:10.1016/j.apmr.2014.02.004. PMC 4071126. PMID 24561056.
Leavitt VM, De Meo E, Riccitelli G, Rocca MA, Comi G, Filippi M, et al. (November 2015). "Elevated body temperature is linked to fatigue in an Italian sample of relapsing-remitting multiple sclerosis patients". Journal of Neurology. 262 (11): 2440–2442. doi:10.1007/s00415-015-7863-8. PMID 26223805.
Loy BD, Taylor RL, Fling BW, Horak FB (September 2017). "Relationship between perceived fatigue and performance fatigability in people with multiple sclerosis: A systematic review and meta-analysis". Journal of Psychosomatic Research. 100: 1–7. doi:10.1016/j.jpsychores.2017.06.017. PMC 5875709. PMID 28789787.
Patejdl R, Zettl UK (2022). "The pathophysiology of motor fatigue and fatigability in multiple sclerosis". Frontiers in Neurology. 13: 891415. doi:10.3389/fneur.2022.891415. PMC 9363784. PMID 35968278.
Chalah MA, Riachi N, Ahdab R, Créange A, Lefaucheur JP, Ayache SS (2015). "Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation". Frontiers in Cellular Neuroscience. 9: 460. doi:10.3389/fncel.2015.00460. PMC 4663273. PMID 26648845.
Gerber LH, Weinstein AA, Mehta R, Younossi ZM (July 2019). "Importance of fatigue and its measurement in chronic liver disease". World Journal of Gastroenterology. 25 (28): 3669–3683. doi:10.3748/wjg.v25.i28.3669. PMC 6676553. PMID 31391765.
Hartvig Honoré P (June 2013). "Fatigue". European Journal of Hospital Pharmacy. 20 (3): 147–148. doi:10.1136/ejhpharm-2013-000309. S2CID 220171226.
Bakshi R (June 2003). "Fatigue associated with multiple sclerosis: diagnosis, impact and management". Multiple Sclerosis. 9 (3): 219–227. doi:10.1191/1352458503ms904oa. PMID 12814166. S2CID 40931716.
Mohr DC, Hart SL, Goldberg A (2003). "Effects of treatment for depression on fatigue in multiple sclerosis". Psychosomatic Medicine. 65 (4): 542–547. CiteSeerX 10.1.1.318.5928. doi:10.1097/01.PSY.0000074757.11682.96. PMID 12883103. S2CID 16239318.
Palotai M, Guttmann CR (June 2020). "Brain anatomical correlates of fatigue in multiple sclerosis". Multiple Sclerosis. 26 (7): 751–764. doi:10.1177/1352458519876032. PMID 31536461.
Camera V, Mariano R, Messina S, Menke R, Griffanti L, Craner M, et al. (2023). "Shared imaging markers of fatigue across multiple sclerosis, aquaporin-4 antibody neuromyelitis optica spectrum disorder and MOG antibody disease". Brain Communications. 5 (3): fcad107. doi:10.1093/braincomms/fcad107. PMC 10171455. PMID 37180990.
Preziosa P, Rocca MA, Pagani E, Valsasina P, Amato MP, Brichetto G, et al. (March 2023). "Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis". Journal of Neurology. 270 (3): 1543–1563. doi:10.1007/s00415-022-11486-0. hdl:10026.1/20405. PMID 36436069.
Novo AM, Batista S, Alves C, d'Almeida OC, Marques IB, Macário C, et al. (December 2018). "The neural basis of fatigue in multiple sclerosis: A multimodal MRI approach". Neurology. Clinical Practice. 8 (6): 492–500. doi:10.1212/CPJ.0000000000000545. PMC 6294533. PMID 30588379.
Bisecco A, Caiazzo G, d'Ambrosio A, Sacco R, Bonavita S, Docimo R, et al. (November 2016). "Fatigue in multiple sclerosis: The contribution of occult white matter damage". Multiple Sclerosis. 22 (13): 1676–1684. doi:10.1177/1352458516628331. PMID 26846989.
Rocca MA, Parisi L, Pagani E, Copetti M, Rodegher M, Colombo B, et al. (November 2014). "Regional but not global brain damage contributes to fatigue in multiple sclerosis". Radiology. 273 (2): 511–520. doi:10.1148/radiol.14140417. PMID 24927473.
Muñoz Maniega S, Chappell FM, Valdés Hernández MC, Armitage PA, Makin SD, Heye AK, et al. (February 2017). "Integrity of normal-appearing white matter: Influence of age, visible lesion burden and hypertension in patients with small-vessel disease". Journal of Cerebral Blood Flow and Metabolism. 37 (2): 644–656. doi:10.1177/0271678X16635657. PMC 5381455. PMID 26933133.
Sepulcre J, Masdeu JC, Goñi J, Arrondo G, Vélez de Mendizábal N, Bejarano B, et al. (March 2009). "Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways". Multiple Sclerosis. 15 (3): 337–344. doi:10.1177/1352458508098373. PMID 18987107. S2CID 2701289.
"Fatigue in early multiple sclerosis: MRI metrics of neuroinflammation, relapse and neurodegeneration". Brain Communications. 6 (5): fcae278. October 1, 2024. doi:10.1093/braincomms/fcae278. PMC 11462441 – via Silverchair.
Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C (January 2007). Pucci E (ed.). "Amantadine for fatigue in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2007 (1): CD002818. doi:10.1002/14651858.CD002818.pub2. PMC 6991937. PMID 17253480.
Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP (August 1992). "A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis". Neurology. 42 (8): 1468–1471. doi:10.1212/wnl.42.8.1468. PMID 1641137. S2CID 41990406.
Mathiowetz VG, Finlayson ML, Matuska KM, Chen HY, Luo P (October 2005). "Randomized controlled trial of an energy conservation course for persons with multiple sclerosis". Multiple Sclerosis. 11 (5): 592–601. doi:10.1191/1352458505ms1198oa. PMID 16193899. S2CID 33902095.
Matuska K, Mathiowetz V, Finlayson M (2007). "Use and perceived effectiveness of energy conservation strategies for managing multiple sclerosis fatigue". The American Journal of Occupational Therapy. 61 (1): 62–69. doi:10.5014/ajot.61.1.62. PMID 17302106.
Pinarello C, Elmers J, Inojosa H, Beste C, Ziemssen T (2023). "Management of multiple sclerosis fatigue in the digital age: from assessment to treatment". Frontiers in Neuroscience. 17: 1231321. doi:10.3389/fnins.2023.1231321. PMC 10585158. PMID 37869507.
Hennessey A, Robertson NP, Swingler R, Compston DA (November 1999). "Urinary, faecal and sexual dysfunction in patients with multiple sclerosis". Journal of Neurology. 246 (11): 1027–1032. doi:10.1007/s004150050508. PMID 10631634. S2CID 30179761.
Burguera-Hernández JA (2000). "[Urinary alterations in multiple sclerosis]". Revista de Neurologia (in Spanish). 30 (10): 989–992. doi:10.33588/rn.3010.99371. PMID 10919202.
Betts CD, D'Mellow MT, Fowler CJ (March 1993). "Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 56 (3): 245–250. doi:10.1136/jnnp.56.3.245. PMC 1014855. PMID 8459239.
Nour S, Svarer C, Kristensen JK, Paulson OB, Law I (April 2000). "Cerebral activation during micturition in normal men". Brain. 123 ( Pt 4) (4): 781–789. doi:10.1093/brain/123.4.781. PMID 10734009.
Ayuso-Peralta L, de Andrés C (2002). "[Symptomatic treatment of multiple sclerosis]". Revista de Neurologia (in Spanish). 35 (12): 1141–1153. doi:10.33588/rn.3512.2002385. PMID 12497297.
Bosma R, Wynia K, Havlíková E, De Keyser J, Middel B (July 2005). "Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis". Acta Neurologica Scandinavica. 112 (1): 1–5. doi:10.1111/j.1600-0404.2005.00431.x. hdl:11370/1eb88003-4dfb-4de1-9aa2-1100972e8666. PMID 15932348. S2CID 46673620.
DasGupta R, Fowler CJ (2003). "Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies". Drugs. 63 (2): 153–166. doi:10.2165/00003495-200363020-00003. PMID 12515563. S2CID 46351374.
Bobholz JA, Rao SM (June 2003). "Cognitive dysfunction in multiple sclerosis: a review of recent developments". Current Opinion in Neurology. 16 (3): 283–288. doi:10.1097/00019052-200306000-00006. PMID 12858063.
Amato MP, Ponziani G, Siracusa G, Sorbi S (October 2001). "Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years". Archives of Neurology. 58 (10): 1602–1606. doi:10.1001/archneur.58.10.1602. PMID 11594918.
Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. (2018). "Recommendations for cognitive screening and management in multiple sclerosis care". Multiple Sclerosis Journal. 24 (13): 1665–1680. doi:10.1177/1352458518803785. PMC 6238181. PMID 30303036.
Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, et al. (2018). "Cognition in multiple sclerosis". Neurology. 90 (6): 278–288. doi:10.1212/WNL.0000000000004977. PMC 5818015. PMID 29343470.
Benedict RH, Carone DA, Bakshi R (July 2004). "Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis". Journal of Neuroimaging. 14 (3 Suppl): 36S – 45S. doi:10.1177/1051228404266267. PMID 15228758.
Shawaryn MA, Schultheis MT, Garay E, Deluca J (August 2002). "Assessing functional status: exploring the relationship between the multiple sclerosis functional composite and driving". Archives of Physical Medicine and Rehabilitation. 83 (8): 1123–1129. doi:10.1053/apmr.2002.33730. PMID 12161835.
Rao SM, Leo GJ, Bernardin L, Unverzagt F (May 1991). "Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction". Neurology. 41 (5): 685–691. doi:10.1212/wnl.41.5.685. PMID 2027484. S2CID 9962959.
Lechner-Scott J, Agland S, Allan M, Darby D, Diamond K, Merlo D, et al. (2023). "Managing cognitive impairment and its impact in multiple sclerosis: An Australian multidisciplinary perspective". Multiple Sclerosis and Related Disorders. 79. doi:10.1016/j.msard.2023.104952. PMID 37683558.
Dujardin K, Donze AC, Hautecoeur P (January 1998). "Attention impairment in recently diagnosed multiple sclerosis". European Journal of Neurology. 5 (1): 61–66. doi:10.1046/j.1468-1331.1998.510061.x. PMID 10210813. S2CID 33389996.
Achiron A, Barak Y (April 2003). "Cognitive impairment in probable multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 74 (4): 443–446. doi:10.1136/jnnp.74.4.443. PMC 1738365. PMID 12640060.
Kletenik I, Cohen AL, Glanz BI, Ferguson MA, Tauhid S, Li J, et al. (November 2023). "Multiple sclerosis lesions that impair memory map to a connected memory circuit". Journal of Neurology. 270 (11): 5211–5222. doi:10.1007/s00415-023-11907-8. PMC 10592111. PMID 37532802. S2CID 260433348.
Chiaravalloti ND, DeLuca J (December 2008). "Cognitive impairment in multiple sclerosis". The Lancet. Neurology. 7 (12): 1139–1151. doi:10.1016/S1474-4422(08)70259-X. PMID 19007738. S2CID 25783642.
Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, et al. (March 1996). "Depression and multiple sclerosis". Neurology. 46 (3): 628–632. doi:10.1212/wnl.46.3.628. PMID 8618657. S2CID 33587300.
Patten SB, Beck CA, Williams JV, Barbui C, Metz LM (December 2003). "Major depression in multiple sclerosis: a population-based perspective". Neurology. 61 (11): 1524–1527. CiteSeerX 10.1.1.581.3646. doi:10.1212/01.wnl.0000095964.34294.b4. PMID 14663036. S2CID 1602489.
Siegert RJ, Abernethy DA (April 2005). "Depression in multiple sclerosis: a review". Journal of Neurology, Neurosurgery, and Psychiatry. 76 (4): 469–475. doi:10.1136/jnnp.2004.054635. PMC 1739575. PMID 15774430.
Sadovnick AD, Eisen K, Ebers GC, Paty DW (August 1991). "Cause of death in patients attending multiple sclerosis clinics". Neurology. 41 (8): 1193–1196. doi:10.1212/wnl.41.8.1193. PMID 1866003. S2CID 31905744.
Leigh RJ, Averbuch-Heller L, Tomsak RL, Remler BF, Yaniglos SS, Dell'Osso LF (August 1994). "Treatment of abnormal eye movements that impair vision: strategies based on current concepts of physiology and pharmacology". Annals of Neurology. 36 (2): 129–141. doi:10.1002/ana.410360204. PMID 8053648. S2CID 23670958.
Starck M, Albrecht H, Pöllmann W, Straube A, Dieterich M (January 1997). "Drug therapy for acquired pendular nystagmus in multiple sclerosis". Journal of Neurology. 244 (1): 9–16. doi:10.1007/PL00007728. PMID 9007739. S2CID 12333107.
Clanet MG, Brassat D (June 2000). "The management of multiple sclerosis patients". Current Opinion in Neurology. 13 (3): 263–270. doi:10.1097/00019052-200006000-00005. PMID 10871249.
Menon GJ, Thaller VT (November 2002). "Therapeutic external ophthalmoplegia with bilateral retrobulbar botulinum toxin- an effective treatment for acquired nystagmus with oscillopsia". Eye. 16 (6): 804–806. doi:10.1038/sj.eye.6700167. PMID 12439689.
Jain S, Proudlock F, Constantinescu CS, Gottlob I (November 2002). "Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis". American Journal of Ophthalmology. 134 (5): 780–782. doi:10.1016/S0002-9394(02)01629-X. PMID 12429265.
Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. (February 1989). "The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability". Brain. 112 ( Pt 1) (1): 133–146. doi:10.1093/brain/112.1.133. PMID 2917275.
Freeman JA (April 2001). "Improving mobility and functional independence in persons with multiple sclerosis". Journal of Neurology. 248 (4): 255–259. doi:10.1007/s004150170198. PMID 11374088. S2CID 12461962.
Beck RW, Trobe JD (October 1995). "What we have learned from the Optic Neuritis Treatment Trial". Ophthalmology. 102 (10): 1504–1508. doi:10.1016/s0161-6420(95)30839-1. PMID 9097798.
Cervetto L, Demontis GC, Gargini C (February 2007). "Cellular mechanisms underlying the pharmacological induction of phosphenes". British Journal of Pharmacology. 150 (4): 383–390. doi:10.1038/sj.bjp.0706998. PMC 2189731. PMID 17211458.
"An intereye difference of 5–6 μm in RNFL thickness is a robust structural threshold for identifying the presence of a unilateral optic nerve lesion in MS." Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C, et al. (December 2018). "Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis". Journal of Neuro-Ophthalmology. 38 (4): 451–458. doi:10.1097/WNO.0000000000000629. PMC 8845082. PMID 29384802.
Jiang H, Delgado S, Wang J (February 2021). "Advances in ophthalmic structural and functional measures in multiple sclerosis: do the potential ocular biomarkers meet the unmet needs?". Current Opinion in Neurology. 34 (1): 97–107. doi:10.1097/WCO.0000000000000897. PMC 7856092. PMID 33278142.
Nij Bijvank J, Uitdehaag BM, Petzold A (February 2022). "Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics". Journal of Neurology, Neurosurgery, and Psychiatry. 93 (2): 216–219. doi:10.1136/jnnp-2021-327468. PMC 8785044. PMID 34764152.
Bsteh G, Hegen H, Altmann P, Auer M, Berek K, Pauli FD, et al. (October 19, 2020). "Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis". Multiple Sclerosis Journal: Experimental, Translational and Clinical. 6 (4): 2055217320966344. doi:10.1177/2055217320966344. PMC 7604994. PMID 33194221.
Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, et al. (May 2016). "Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study". The Lancet. Neurology. 15 (6): 574–584. doi:10.1016/S1474-4422(16)00068-5. PMID 27011339.
Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, et al. (May 2013). "Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis". Pain. 154 (5): 632–642. doi:10.1016/j.pain.2012.12.002. PMID 23318126. S2CID 25807525.
"Comorbidity is associated with pain-related activity limitations in multiple sclerosis". Multiple Sclerosis and Related Disorders. 4 (5): 470–476. September 17, 2015. doi:10.1016/j.msard.2015.07.014. PMID 26346797 – via PubMed.
Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, et al. (July 1994). "Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients". Pain. 58 (1): 89–93. doi:10.1016/0304-3959(94)90188-0. PMID 7970843. S2CID 25295712.
Solaro C, Messmer Uccelli M, Uccelli A, Leandri M, Mancardi GL (2000). "Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis". European Neurology. 44 (1): 45–48. doi:10.1159/000008192. hdl:11567/301010. PMID 10894995. S2CID 39508538.
Kondziolka D, Lunsford LD, Bissonette DJ (May 1994). "Long-term results after glycerol rhizotomy for multiple sclerosis-related trigeminal neuralgia". The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques. 21 (2): 137–140. doi:10.1017/S0317167100049076. PMID 8087740.
Athanasiou TC, Patel NK, Renowden SA, Coakham HB (December 2005). "Some patients with multiple sclerosis have neurovascular compression causing their trigeminal neuralgia and can be treated effectively with MVD: report of five cases". British Journal of Neurosurgery. 19 (6): 463–468. doi:10.1080/02688690500495067. PMID 16574557. S2CID 33819410.
Eldridge PR, Sinha AK, Javadpour M, Littlechild P, Varma TR (2003). "Microvascular decompression for trigeminal neuralgia in patients with multiple sclerosis". Stereotactic and Functional Neurosurgery. 81 (1–4): 57–64. doi:10.1159/000075105. PMID 14742965. S2CID 39449873.
Gutrecht JA, Zamani AA, Slagado ED (August 1993). "Anatomic-radiologic basis of Lhermitte's sign in multiple sclerosis". Archives of Neurology. 50 (8): 849–851. doi:10.1001/archneur.1993.00540080056014. PMID 8352672.
Al-Araji AH, Oger J (August 2005). "Reappraisal of Lhermitte's sign in multiple sclerosis". Multiple Sclerosis. 11 (4): 398–402. doi:10.1191/1352458505ms1177oa. PMID 16042221. S2CID 33610136.
Sandyk R, Dann LC (April 1995). "Resolution of Lhermitte's sign in multiple sclerosis by treatment with weak electromagnetic fields". The International Journal of Neuroscience. 81 (3–4): 215–224. doi:10.3109/00207459509004888. PMID 7628912.
Kanchandani R, Howe JG (April 1982). "Lhermitte's sign in multiple sclerosis: a clinical survey and review of the literature". Journal of Neurology, Neurosurgery, and Psychiatry. 45 (4): 308–312. doi:10.1136/jnnp.45.4.308. PMC 491365. PMID 7077340.
Moulin DE, Foley KM, Ebers GC (December 1988). "Pain syndromes in multiple sclerosis". Neurology. 38 (12): 1830–1834. doi:10.1212/wnl.38.12.1830. PMID 2973568. S2CID 647138.
Schmidt FA, Maas MB, Geran R, Schmidt C, Kunte H, Ruprecht K, et al. (July 2017). "Olfactory dysfunction in patients with primary progressive MS". Neurology. 4 (4): e369. doi:10.1212/NXI.0000000000000369. PMC 5471346. PMID 28638852. S2CID 1080966.
Atalar AÇ, Erdal Y, Tekin B, Yıldız M, Akdoğan Ö, Emre U (April 2018). "Olfactory dysfunction in multiple sclerosis". Multiple Sclerosis and Related Disorders. 21: 92–96. doi:10.1016/j.msard.2018.02.032. PMID 29529530.
Lakhan SE, Rowland M (December 2009). "Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review". BMC Neurology. 9: 59. doi:10.1186/1471-2377-9-59. PMC 2793241. PMID 19961570.
Beard S, Hunn A, Wight J (2003). "Treatments for spasticity and pain in multiple sclerosis: a systematic review". Health Technology Assessment. 7 (40): iii, ix–x, 1–111. doi:10.3310/hta7400. PMID 14636486.
Paisley S, Beard S, Hunn A, Wight J (August 2002). "Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review". Multiple Sclerosis. 8 (4): 319–329. doi:10.1191/1352458502ms795rr. PMID 12166503. S2CID 1641319.
Becker WJ, Harris CJ, Long ML, Ablett DP, Klein GM, DeForge DA (August 1995). "Long-term intrathecal baclofen therapy in patients with intractable spasticity". The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques. 22 (3): 208–217. doi:10.1017/S031716710003986X. PMID 8529173.
Asnafi S, Morris PP, Sechi E, Pittock SJ, Weinshenker BG, Palace J, et al. (January 2020). "The frequency of longitudinally extensive transverse myelitis in MS: A population-based study". Multiple Sclerosis and Related Disorders. 37: 101487. doi:10.1016/j.msard.2019.101487. PMID 31707235.
Koch M, Mostert J, Heersema D, De Keyser J (February 2007). "Tremor in multiple sclerosis". Journal of Neurology. 254 (2): 133–145. doi:10.1007/s00415-006-0296-7. PMC 1915650. PMID 17318714.
Bozek CB, Kastrukoff LF, Wright JM, Perry TL, Larsen TA (January 1987). "A controlled trial of isoniazid therapy for action tremor in multiple sclerosis". Journal of Neurology. 234 (1): 36–39. doi:10.1007/BF00314007. PMID 3546605. S2CID 23597601.
Duquette P, Pleines J, du Souich P (December 1985). "Isoniazid for tremor in multiple sclerosis: a controlled trial". Neurology. 35 (12): 1772–1775. doi:10.1212/wnl.35.12.1772. PMID 3906430. S2CID 24266989.
Hallett M, Lindsey JW, Adelstein BD, Riley PO (September 1985). "Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis". Neurology. 35 (9): 1374–1377. doi:10.1212/wnl.35.9.1374. PMID 3895037. S2CID 30254514.
Koller WC (March 1984). "Pharmacologic trials in the treatment of cerebellar tremor". Archives of Neurology. 41 (3): 280–281. doi:10.1001/archneur.1984.04050150058017. PMID 6365047.
Sechi GP, Zuddas M, Piredda M, Agnetti V, Sau G, Piras ML, et al. (August 1989). "Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up". Neurology. 39 (8): 1113–1115. doi:10.1212/wnl.39.8.1113. PMID 2668787. S2CID 36050520.
Aisen ML, Holzer M, Rosen M, Dietz M, McDowell F (May 1991). "Glutethimide treatment of disabling action tremor in patients with multiple sclerosis and traumatic brain injury". Archives of Neurology. 48 (5): 513–515. doi:10.1001/archneur.1991.00530170077023. PMID 2021365.
Mills RJ, Yap L, Young CA (January 2007). Mills RJ (ed.). "Treatment for ataxia in multiple sclerosis". The Cochrane Database of Systematic Reviews (1): CD005029. doi:10.1002/14651858.CD005029.pub2. PMID 17253537.
Aisen ML, Arnold A, Baiges I, Maxwell S, Rosen M (July 1993). "The effect of mechanical damping loads on disabling action tremor". Neurology. 43 (7): 1346–1350. doi:10.1212/wnl.43.7.1346. PMID 8327136. S2CID 23433712.
Bittar RG, Hyam J, Nandi D, Wang S, Liu X, Joint C, et al. (August 2005). "Thalamotomy versus thalamic stimulation for multiple sclerosis tremor". Journal of Clinical Neuroscience. 12 (6): 638–642. doi:10.1016/j.jocn.2004.09.008. PMID 16098758. S2CID 38770179.
Odintsova TA, Kopchak OO (2021). "Sleep Disorders in Relapsing-Remitting Multiple Sclerosis Patients" (PDF). Wiadomości Lekarskie. 74 (2): 257–262. doi:10.36740/WLek202102115. PMID 33813482.
Stanton BR, Barnes F, Silber E (2006). "Sleep and fatigue in multiple sclerosis". Multiple Sclerosis Journal. 12 (4): 481–486. doi:10.1191/135248506ms1320oa. PMID 16900762.
Laslett LL, Honan C, Turner JA, Dagnew B, Campbell JA, Gill TK, et al. (2022). "Poor sleep and multiple sclerosis: Associations with symptoms of multiple sclerosis and quality of life". Journal of Neurology, Neurosurgery & Psychiatry. 93 (11): 1162–1165. doi:10.1136/jnnp-2022-329227. PMID 35896381.
Patel KS, Dunn KM, Brown A, Opelt B, Hughes AJ, Hughes AJ (2023). "Sleep disturbance and fatigue in multiple sclerosis: A systematic review and meta-analysis". Multiple Sclerosis Journal - Experimental, Translational and Clinical. 9 (3). doi:10.1177/20552173231194352. PMC 10460472. PMID 37641617.
Strober LB (2015). "Fatigue in Multiple Sclerosis: A Look at the Role of Poor Sleep". Frontiers in Neurology. 6: 21. doi:10.3389/fneur.2015.00021. PMC 4325921. PMID 25729378.

handle.net

hdl.handle.net

Preziosa P, Rocca MA, Pagani E, Valsasina P, Amato MP, Brichetto G, et al. (March 2023). "Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis". Journal of Neurology. 270 (3): 1543–1563. doi:10.1007/s00415-022-11486-0. hdl:10026.1/20405. PMID 36436069.
Bosma R, Wynia K, Havlíková E, De Keyser J, Middel B (July 2005). "Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis". Acta Neurologica Scandinavica. 112 (1): 1–5. doi:10.1111/j.1600-0404.2005.00431.x. hdl:11370/1eb88003-4dfb-4de1-9aa2-1100972e8666. PMID 15932348. S2CID 46673620.
Solaro C, Messmer Uccelli M, Uccelli A, Leandri M, Mancardi GL (2000). "Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis". European Neurology. 44 (1): 45–48. doi:10.1159/000008192. hdl:11567/301010. PMID 10894995. S2CID 39508538.

masterhealth.care

"MS Hug: 7 Tips for Relieving MS Hug Symptoms". November 25, 2022.

medlineplus.gov

"Alfuzosin". MedlinePlus Drug Information. U.S. National Library of Medicine.
"Trospium". MedlinePlus Drug Information. U.S. National Library of Medicine.
"Flavoxate". MedlinePlus Drug Information. U.S. National Library of Medicine.
"Carbamazepine". MedlinePlus Drug Information. U.S. National Library of Medicine.
"Phenytoin". MedlinePlus Drug Information. U.S. National Library of Medicine.
"Gabapentin". MedlinePlus Drug Information. U.S. National Library of Medicine.
"Clonazepam". MedlinePlus Drug Information. U.S. National Library of Medicine.
"Amitriptyline". MedlinePlus Drug Information. U.S. National Library of Medicine.
"Propranolol (Cardiovascular)". MedlinePlus Drug Information. U.S. National Library of Medicine.

medscape.com

emedicine.medscape.com

Dyro FM (8 August 2019). Egan RA (ed.). "Urologic Management in Neurologic Disease: Overview, Neuroanatomy of Pelvic Floor, Neurophysiology of Pelvic Floor" – via eMedicine.

ms-uk.org

"Smell test might predict DMT affectiveness". 4 April 2022.

msaustralia.org.au

"Heat Sensitivity". Archived from the original on 2024-01-17. Retrieved 2024-03-15.

mssociety.org.uk

"Relapsing remitting MS (RRMS)". mssociety.org. Retrieved 2024-04-23.
"Understanding MS Spasms and Stiffness | MS Society". www.mssociety.org.uk.

mstrust.org.uk

"Fatigue". mstrust.org.uk.
"Fatigue". Letchworth Garden City, United Kingdom: Multiple Sclerosis Trust.
Trust MS. "Temperature sensitivity | MS Trust". mstrust.org.uk. Archived from the original on 2024-01-17. Retrieved 2024-03-15.
"Temperature sensitivity". mstrust.org.uk. Archived from the original on 2024-01-17. Retrieved 2024-03-15.
Trust MS. "Pain | MS Trust". mstrust.org.uk.
Trust MS. "Spasticity and spasms | MS Trust". mstrust.org.uk.
Trust MS. "Speech problems | MS Trust". mstrust.org.uk.
"Sleep and MS | MS Trust".

mymsaa.org

"Cognitive Changes". 23 December 2015.
Communications H (December 23, 2015). "Speech Difficulties". MSAA.

nationalmssociety.org

"Empowering people affected by MS to live their best lives". National Multiple Sclerosis Society.
"Empowering people affected by MS to live their best lives". National Multiple Sclerosis Society.
"Empowering people affected by MS to live their best lives".

neurologylive.com

"Effects of Long-term CPAP Therapy in Multiple Sclerosis: Daria Trojan, MD, MSC". 15 November 2023.

nice.org.uk

"Recommendations | Multiple sclerosis in adults: management | Guidance | NICE". www.nice.org.uk. June 22, 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kurtzke JF (November 1983). "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)". Neurology. 33 (11): 1444–1452. doi:10.1212/WNL.33.11.1444. PMID 6685237.
Navarro S, Mondéjar-Marín B, Pedrosa-Guerrero A, Pérez-Molina I, Garrido-Robres JA, Alvarez-Tejerina A (2005). "[Aphasia and parietal syndrome as the presenting symptoms of a demyelinating disease with pseudotumoral lesions]". Revista de Neurologia. 41 (10): 601–603. PMID 16288423.
Jongen PJ (June 2006). "Psychiatric onset of multiple sclerosis". Journal of the Neurological Sciences. 245 (1–2): 59–62. doi:10.1016/j.jns.2005.09.014. PMID 16631798. S2CID 33098365.
Paty D, Studney D, Redekop K, Lublin F (1994). "MS COSTAR: a computerized patient record adapted for clinical research purposes". Annals of Neurology. 36 (Suppl): S134 – S135. doi:10.1002/ana.410360732. PMID 8017875. S2CID 23425667.
Moore H, Nair KP, Baster K, Middleton R, Paling D, Sharrack B (August 2022). "Fatigue in multiple sclerosis: A UK MS-register based study". Multiple Sclerosis and Related Disorders. 64: 103954. doi:10.1016/j.msard.2022.103954. PMID 35716477.
Hubbard AL, Golla H, Lausberg H (June 2021). "What's in a name? That which we call Multiple Sclerosis Fatigue". Multiple Sclerosis. 27 (7): 983–988. doi:10.1177/1352458520941481. PMC 8142120. PMID 32672087.
Bakalidou D, Giannopapas V, Giannopoulos S (July 2023). "Thoughts on Fatigue in Multiple Sclerosis Patients". Cureus. 15 (7): e42146. doi:10.7759/cureus.42146. PMC 10438195. PMID 37602098.
Tervonen T, Fox RJ, Brooks A, Sidorenko T, Boyanova N, Levitan B, et al. (2023). "Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment". Multiple Sclerosis Journal: Experimental, Translational and Clinical. 9 (1): 20552173221150370. doi:10.1177/20552173221150370. PMC 9880588. PMID 36714174.
Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, et al. (June 2019). "Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 90 (6): 642–651. doi:10.1136/jnnp-2018-320050. PMC 6581095. PMID 30683707.
Ellison PM, Goodall S, Kennedy N, Dawes H, Clark A, Pomeroy V, et al. (September 2022). "Neurostructural and Neurophysiological Correlates of Multiple Sclerosis Physical Fatigue: Systematic Review and Meta-Analysis of Cross-Sectional Studies". Neuropsychology Review. 32 (3): 506–519. doi:10.1007/s11065-021-09508-1. PMC 9381450. PMID 33961198.
Newland P, Starkweather A, Sorenson M (July 2016). "Central fatigue in multiple sclerosis: a review of the literature". The Journal of Spinal Cord Medicine. 39 (4): 386–399. doi:10.1080/10790268.2016.1168587. PMC 5102292. PMID 27146427.
Chen MH, Wylie GR, Sandroff BM, Dacosta-Aguayo R, DeLuca J, Genova HM (August 2020). "Neural mechanisms underlying state mental fatigue in multiple sclerosis: a pilot study". Journal of Neurology. 267 (8): 2372–2382. doi:10.1007/s00415-020-09853-w. PMID 32350648.
Christogianni A, O'Garro J, Bibb R, Filtness A, Filingeri D (November 2022). "Heat and cold sensitivity in multiple sclerosis: A patient-centred perspective on triggers, symptoms, and thermal resilience practices". Multiple Sclerosis and Related Disorders. 67: 104075. doi:10.1016/j.msard.2022.104075. PMID 35963205.
Davis SL, Wilson TE, White AT, Frohman EM (November 2010). "Thermoregulation in multiple sclerosis". Journal of Applied Physiology. 109 (5): 1531–1537. doi:10.1152/japplphysiol.00460.2010. PMC 2980380. PMID 20671034.
Sumowski JF, Leavitt VM (July 2014). "Body temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure". Archives of Physical Medicine and Rehabilitation. 95 (7): 1298–1302. doi:10.1016/j.apmr.2014.02.004. PMC 4071126. PMID 24561056.
Leavitt VM, De Meo E, Riccitelli G, Rocca MA, Comi G, Filippi M, et al. (November 2015). "Elevated body temperature is linked to fatigue in an Italian sample of relapsing-remitting multiple sclerosis patients". Journal of Neurology. 262 (11): 2440–2442. doi:10.1007/s00415-015-7863-8. PMID 26223805.
Loy BD, Taylor RL, Fling BW, Horak FB (September 2017). "Relationship between perceived fatigue and performance fatigability in people with multiple sclerosis: A systematic review and meta-analysis". Journal of Psychosomatic Research. 100: 1–7. doi:10.1016/j.jpsychores.2017.06.017. PMC 5875709. PMID 28789787.
Patejdl R, Zettl UK (2022). "The pathophysiology of motor fatigue and fatigability in multiple sclerosis". Frontiers in Neurology. 13: 891415. doi:10.3389/fneur.2022.891415. PMC 9363784. PMID 35968278.
Chalah MA, Riachi N, Ahdab R, Créange A, Lefaucheur JP, Ayache SS (2015). "Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation". Frontiers in Cellular Neuroscience. 9: 460. doi:10.3389/fncel.2015.00460. PMC 4663273. PMID 26648845.
Gerber LH, Weinstein AA, Mehta R, Younossi ZM (July 2019). "Importance of fatigue and its measurement in chronic liver disease". World Journal of Gastroenterology. 25 (28): 3669–3683. doi:10.3748/wjg.v25.i28.3669. PMC 6676553. PMID 31391765.
Bakshi R (June 2003). "Fatigue associated with multiple sclerosis: diagnosis, impact and management". Multiple Sclerosis. 9 (3): 219–227. doi:10.1191/1352458503ms904oa. PMID 12814166. S2CID 40931716.
Mohr DC, Hart SL, Goldberg A (2003). "Effects of treatment for depression on fatigue in multiple sclerosis". Psychosomatic Medicine. 65 (4): 542–547. CiteSeerX 10.1.1.318.5928. doi:10.1097/01.PSY.0000074757.11682.96. PMID 12883103. S2CID 16239318.
Palotai M, Guttmann CR (June 2020). "Brain anatomical correlates of fatigue in multiple sclerosis". Multiple Sclerosis. 26 (7): 751–764. doi:10.1177/1352458519876032. PMID 31536461.
Camera V, Mariano R, Messina S, Menke R, Griffanti L, Craner M, et al. (2023). "Shared imaging markers of fatigue across multiple sclerosis, aquaporin-4 antibody neuromyelitis optica spectrum disorder and MOG antibody disease". Brain Communications. 5 (3): fcad107. doi:10.1093/braincomms/fcad107. PMC 10171455. PMID 37180990.
Preziosa P, Rocca MA, Pagani E, Valsasina P, Amato MP, Brichetto G, et al. (March 2023). "Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis". Journal of Neurology. 270 (3): 1543–1563. doi:10.1007/s00415-022-11486-0. hdl:10026.1/20405. PMID 36436069.
Novo AM, Batista S, Alves C, d'Almeida OC, Marques IB, Macário C, et al. (December 2018). "The neural basis of fatigue in multiple sclerosis: A multimodal MRI approach". Neurology. Clinical Practice. 8 (6): 492–500. doi:10.1212/CPJ.0000000000000545. PMC 6294533. PMID 30588379.
Bisecco A, Caiazzo G, d'Ambrosio A, Sacco R, Bonavita S, Docimo R, et al. (November 2016). "Fatigue in multiple sclerosis: The contribution of occult white matter damage". Multiple Sclerosis. 22 (13): 1676–1684. doi:10.1177/1352458516628331. PMID 26846989.
Rocca MA, Parisi L, Pagani E, Copetti M, Rodegher M, Colombo B, et al. (November 2014). "Regional but not global brain damage contributes to fatigue in multiple sclerosis". Radiology. 273 (2): 511–520. doi:10.1148/radiol.14140417. PMID 24927473.
Muñoz Maniega S, Chappell FM, Valdés Hernández MC, Armitage PA, Makin SD, Heye AK, et al. (February 2017). "Integrity of normal-appearing white matter: Influence of age, visible lesion burden and hypertension in patients with small-vessel disease". Journal of Cerebral Blood Flow and Metabolism. 37 (2): 644–656. doi:10.1177/0271678X16635657. PMC 5381455. PMID 26933133.
Sepulcre J, Masdeu JC, Goñi J, Arrondo G, Vélez de Mendizábal N, Bejarano B, et al. (March 2009). "Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways". Multiple Sclerosis. 15 (3): 337–344. doi:10.1177/1352458508098373. PMID 18987107. S2CID 2701289.
Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C (January 2007). Pucci E (ed.). "Amantadine for fatigue in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2007 (1): CD002818. doi:10.1002/14651858.CD002818.pub2. PMC 6991937. PMID 17253480.
Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP (August 1992). "A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis". Neurology. 42 (8): 1468–1471. doi:10.1212/wnl.42.8.1468. PMID 1641137. S2CID 41990406.
Mathiowetz VG, Finlayson ML, Matuska KM, Chen HY, Luo P (October 2005). "Randomized controlled trial of an energy conservation course for persons with multiple sclerosis". Multiple Sclerosis. 11 (5): 592–601. doi:10.1191/1352458505ms1198oa. PMID 16193899. S2CID 33902095.
Matuska K, Mathiowetz V, Finlayson M (2007). "Use and perceived effectiveness of energy conservation strategies for managing multiple sclerosis fatigue". The American Journal of Occupational Therapy. 61 (1): 62–69. doi:10.5014/ajot.61.1.62. PMID 17302106.
Pinarello C, Elmers J, Inojosa H, Beste C, Ziemssen T (2023). "Management of multiple sclerosis fatigue in the digital age: from assessment to treatment". Frontiers in Neuroscience. 17: 1231321. doi:10.3389/fnins.2023.1231321. PMC 10585158. PMID 37869507.
Hennessey A, Robertson NP, Swingler R, Compston DA (November 1999). "Urinary, faecal and sexual dysfunction in patients with multiple sclerosis". Journal of Neurology. 246 (11): 1027–1032. doi:10.1007/s004150050508. PMID 10631634. S2CID 30179761.
Burguera-Hernández JA (2000). "[Urinary alterations in multiple sclerosis]". Revista de Neurologia (in Spanish). 30 (10): 989–992. doi:10.33588/rn.3010.99371. PMID 10919202.
Betts CD, D'Mellow MT, Fowler CJ (March 1993). "Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 56 (3): 245–250. doi:10.1136/jnnp.56.3.245. PMC 1014855. PMID 8459239.
Nour S, Svarer C, Kristensen JK, Paulson OB, Law I (April 2000). "Cerebral activation during micturition in normal men". Brain. 123 ( Pt 4) (4): 781–789. doi:10.1093/brain/123.4.781. PMID 10734009.
Ayuso-Peralta L, de Andrés C (2002). "[Symptomatic treatment of multiple sclerosis]". Revista de Neurologia (in Spanish). 35 (12): 1141–1153. doi:10.33588/rn.3512.2002385. PMID 12497297.
Bosma R, Wynia K, Havlíková E, De Keyser J, Middel B (July 2005). "Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis". Acta Neurologica Scandinavica. 112 (1): 1–5. doi:10.1111/j.1600-0404.2005.00431.x. hdl:11370/1eb88003-4dfb-4de1-9aa2-1100972e8666. PMID 15932348. S2CID 46673620.
The National Collaborating Centre for Chronic Conditions (UK) (2004). "Diagnosis and treatment of specific impairments". Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care (PDF). NICE Clinical Guidelines. Vol. 8. London: Royal College of Physicians (UK). pp. 87–132. ISBN 978-1-86016-182-7. PMID 21290636. Retrieved 6 February 2013.
DasGupta R, Fowler CJ (2003). "Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies". Drugs. 63 (2): 153–166. doi:10.2165/00003495-200363020-00003. PMID 12515563. S2CID 46351374.
Bobholz JA, Rao SM (June 2003). "Cognitive dysfunction in multiple sclerosis: a review of recent developments". Current Opinion in Neurology. 16 (3): 283–288. doi:10.1097/00019052-200306000-00006. PMID 12858063.
Amato MP, Ponziani G, Siracusa G, Sorbi S (October 2001). "Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years". Archives of Neurology. 58 (10): 1602–1606. doi:10.1001/archneur.58.10.1602. PMID 11594918.
Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. (2018). "Recommendations for cognitive screening and management in multiple sclerosis care". Multiple Sclerosis Journal. 24 (13): 1665–1680. doi:10.1177/1352458518803785. PMC 6238181. PMID 30303036.
Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, et al. (2018). "Cognition in multiple sclerosis". Neurology. 90 (6): 278–288. doi:10.1212/WNL.0000000000004977. PMC 5818015. PMID 29343470.
Benedict RH, Carone DA, Bakshi R (July 2004). "Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis". Journal of Neuroimaging. 14 (3 Suppl): 36S – 45S. doi:10.1177/1051228404266267. PMID 15228758.
Shawaryn MA, Schultheis MT, Garay E, Deluca J (August 2002). "Assessing functional status: exploring the relationship between the multiple sclerosis functional composite and driving". Archives of Physical Medicine and Rehabilitation. 83 (8): 1123–1129. doi:10.1053/apmr.2002.33730. PMID 12161835.
Rao SM, Leo GJ, Bernardin L, Unverzagt F (May 1991). "Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction". Neurology. 41 (5): 685–691. doi:10.1212/wnl.41.5.685. PMID 2027484. S2CID 9962959.
Lechner-Scott J, Agland S, Allan M, Darby D, Diamond K, Merlo D, et al. (2023). "Managing cognitive impairment and its impact in multiple sclerosis: An Australian multidisciplinary perspective". Multiple Sclerosis and Related Disorders. 79. doi:10.1016/j.msard.2023.104952. PMID 37683558.
Dujardin K, Donze AC, Hautecoeur P (January 1998). "Attention impairment in recently diagnosed multiple sclerosis". European Journal of Neurology. 5 (1): 61–66. doi:10.1046/j.1468-1331.1998.510061.x. PMID 10210813. S2CID 33389996.
Achiron A, Barak Y (April 2003). "Cognitive impairment in probable multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 74 (4): 443–446. doi:10.1136/jnnp.74.4.443. PMC 1738365. PMID 12640060.
Kletenik I, Cohen AL, Glanz BI, Ferguson MA, Tauhid S, Li J, et al. (November 2023). "Multiple sclerosis lesions that impair memory map to a connected memory circuit". Journal of Neurology. 270 (11): 5211–5222. doi:10.1007/s00415-023-11907-8. PMC 10592111. PMID 37532802. S2CID 260433348.
Chiaravalloti ND, DeLuca J (December 2008). "Cognitive impairment in multiple sclerosis". The Lancet. Neurology. 7 (12): 1139–1151. doi:10.1016/S1474-4422(08)70259-X. PMID 19007738. S2CID 25783642.
Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, et al. (March 1996). "Depression and multiple sclerosis". Neurology. 46 (3): 628–632. doi:10.1212/wnl.46.3.628. PMID 8618657. S2CID 33587300.
Patten SB, Beck CA, Williams JV, Barbui C, Metz LM (December 2003). "Major depression in multiple sclerosis: a population-based perspective". Neurology. 61 (11): 1524–1527. CiteSeerX 10.1.1.581.3646. doi:10.1212/01.wnl.0000095964.34294.b4. PMID 14663036. S2CID 1602489.
Siegert RJ, Abernethy DA (April 2005). "Depression in multiple sclerosis: a review". Journal of Neurology, Neurosurgery, and Psychiatry. 76 (4): 469–475. doi:10.1136/jnnp.2004.054635. PMC 1739575. PMID 15774430.
Sadovnick AD, Eisen K, Ebers GC, Paty DW (August 1991). "Cause of death in patients attending multiple sclerosis clinics". Neurology. 41 (8): 1193–1196. doi:10.1212/wnl.41.8.1193. PMID 1866003. S2CID 31905744.
Leigh RJ, Averbuch-Heller L, Tomsak RL, Remler BF, Yaniglos SS, Dell'Osso LF (August 1994). "Treatment of abnormal eye movements that impair vision: strategies based on current concepts of physiology and pharmacology". Annals of Neurology. 36 (2): 129–141. doi:10.1002/ana.410360204. PMID 8053648. S2CID 23670958.
Starck M, Albrecht H, Pöllmann W, Straube A, Dieterich M (January 1997). "Drug therapy for acquired pendular nystagmus in multiple sclerosis". Journal of Neurology. 244 (1): 9–16. doi:10.1007/PL00007728. PMID 9007739. S2CID 12333107.
Clanet MG, Brassat D (June 2000). "The management of multiple sclerosis patients". Current Opinion in Neurology. 13 (3): 263–270. doi:10.1097/00019052-200006000-00005. PMID 10871249.
Menon GJ, Thaller VT (November 2002). "Therapeutic external ophthalmoplegia with bilateral retrobulbar botulinum toxin- an effective treatment for acquired nystagmus with oscillopsia". Eye. 16 (6): 804–806. doi:10.1038/sj.eye.6700167. PMID 12439689.
Jain S, Proudlock F, Constantinescu CS, Gottlob I (November 2002). "Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis". American Journal of Ophthalmology. 134 (5): 780–782. doi:10.1016/S0002-9394(02)01629-X. PMID 12429265.
Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. (February 1989). "The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability". Brain. 112 ( Pt 1) (1): 133–146. doi:10.1093/brain/112.1.133. PMID 2917275.
Freeman JA (April 2001). "Improving mobility and functional independence in persons with multiple sclerosis". Journal of Neurology. 248 (4): 255–259. doi:10.1007/s004150170198. PMID 11374088. S2CID 12461962.
Beck RW, Trobe JD (October 1995). "What we have learned from the Optic Neuritis Treatment Trial". Ophthalmology. 102 (10): 1504–1508. doi:10.1016/s0161-6420(95)30839-1. PMID 9097798.
"The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. 1997". Neurology. 57 (12 Suppl 5): S36 – S45. December 2001. PMID 11902594.
Cervetto L, Demontis GC, Gargini C (February 2007). "Cellular mechanisms underlying the pharmacological induction of phosphenes". British Journal of Pharmacology. 150 (4): 383–390. doi:10.1038/sj.bjp.0706998. PMC 2189731. PMID 17211458.
"An intereye difference of 5–6 μm in RNFL thickness is a robust structural threshold for identifying the presence of a unilateral optic nerve lesion in MS." Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C, et al. (December 2018). "Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis". Journal of Neuro-Ophthalmology. 38 (4): 451–458. doi:10.1097/WNO.0000000000000629. PMC 8845082. PMID 29384802.
Jiang H, Delgado S, Wang J (February 2021). "Advances in ophthalmic structural and functional measures in multiple sclerosis: do the potential ocular biomarkers meet the unmet needs?". Current Opinion in Neurology. 34 (1): 97–107. doi:10.1097/WCO.0000000000000897. PMC 7856092. PMID 33278142.
Nij Bijvank J, Uitdehaag BM, Petzold A (February 2022). "Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics". Journal of Neurology, Neurosurgery, and Psychiatry. 93 (2): 216–219. doi:10.1136/jnnp-2021-327468. PMC 8785044. PMID 34764152.
Bsteh G, Hegen H, Altmann P, Auer M, Berek K, Pauli FD, et al. (October 19, 2020). "Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis". Multiple Sclerosis Journal: Experimental, Translational and Clinical. 6 (4): 2055217320966344. doi:10.1177/2055217320966344. PMC 7604994. PMID 33194221.
Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, et al. (May 2016). "Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study". The Lancet. Neurology. 15 (6): 574–584. doi:10.1016/S1474-4422(16)00068-5. PMID 27011339.
Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, et al. (May 2013). "Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis". Pain. 154 (5): 632–642. doi:10.1016/j.pain.2012.12.002. PMID 23318126. S2CID 25807525.
"Comorbidity is associated with pain-related activity limitations in multiple sclerosis". Multiple Sclerosis and Related Disorders. 4 (5): 470–476. September 17, 2015. doi:10.1016/j.msard.2015.07.014. PMID 26346797 – via PubMed.
Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, et al. (July 1994). "Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients". Pain. 58 (1): 89–93. doi:10.1016/0304-3959(94)90188-0. PMID 7970843. S2CID 25295712.
Kerns RD, Kassirer M, Otis J (2002). "Pain in multiple sclerosis: a biopsychosocial perspective". Journal of Rehabilitation Research and Development. 39 (2): 225–232. PMID 12051466.
Solaro C, Messmer Uccelli M, Uccelli A, Leandri M, Mancardi GL (2000). "Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis". European Neurology. 44 (1): 45–48. doi:10.1159/000008192. hdl:11567/301010. PMID 10894995. S2CID 39508538.
Kondziolka D, Lunsford LD, Bissonette DJ (May 1994). "Long-term results after glycerol rhizotomy for multiple sclerosis-related trigeminal neuralgia". The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques. 21 (2): 137–140. doi:10.1017/S0317167100049076. PMID 8087740.
Athanasiou TC, Patel NK, Renowden SA, Coakham HB (December 2005). "Some patients with multiple sclerosis have neurovascular compression causing their trigeminal neuralgia and can be treated effectively with MVD: report of five cases". British Journal of Neurosurgery. 19 (6): 463–468. doi:10.1080/02688690500495067. PMID 16574557. S2CID 33819410.
Eldridge PR, Sinha AK, Javadpour M, Littlechild P, Varma TR (2003). "Microvascular decompression for trigeminal neuralgia in patients with multiple sclerosis". Stereotactic and Functional Neurosurgery. 81 (1–4): 57–64. doi:10.1159/000075105. PMID 14742965. S2CID 39449873.
Gutrecht JA, Zamani AA, Slagado ED (August 1993). "Anatomic-radiologic basis of Lhermitte's sign in multiple sclerosis". Archives of Neurology. 50 (8): 849–851. doi:10.1001/archneur.1993.00540080056014. PMID 8352672.
Al-Araji AH, Oger J (August 2005). "Reappraisal of Lhermitte's sign in multiple sclerosis". Multiple Sclerosis. 11 (4): 398–402. doi:10.1191/1352458505ms1177oa. PMID 16042221. S2CID 33610136.
Sandyk R, Dann LC (April 1995). "Resolution of Lhermitte's sign in multiple sclerosis by treatment with weak electromagnetic fields". The International Journal of Neuroscience. 81 (3–4): 215–224. doi:10.3109/00207459509004888. PMID 7628912.
Kanchandani R, Howe JG (April 1982). "Lhermitte's sign in multiple sclerosis: a clinical survey and review of the literature". Journal of Neurology, Neurosurgery, and Psychiatry. 45 (4): 308–312. doi:10.1136/jnnp.45.4.308. PMC 491365. PMID 7077340.
Moulin DE, Foley KM, Ebers GC (December 1988). "Pain syndromes in multiple sclerosis". Neurology. 38 (12): 1830–1834. doi:10.1212/wnl.38.12.1830. PMID 2973568. S2CID 647138.
Schmidt FA, Maas MB, Geran R, Schmidt C, Kunte H, Ruprecht K, et al. (July 2017). "Olfactory dysfunction in patients with primary progressive MS". Neurology. 4 (4): e369. doi:10.1212/NXI.0000000000000369. PMC 5471346. PMID 28638852. S2CID 1080966.
Atalar AÇ, Erdal Y, Tekin B, Yıldız M, Akdoğan Ö, Emre U (April 2018). "Olfactory dysfunction in multiple sclerosis". Multiple Sclerosis and Related Disorders. 21: 92–96. doi:10.1016/j.msard.2018.02.032. PMID 29529530.
Cardini RG, Crippa AC, Cattaneo D (May 2000). "Update on multiple sclerosis rehabilitation". Journal of Neurovirology. 6 (Suppl 2): S179 – S185. PMID 10871810.
Lakhan SE, Rowland M (December 2009). "Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review". BMC Neurology. 9: 59. doi:10.1186/1471-2377-9-59. PMC 2793241. PMID 19961570.
Beard S, Hunn A, Wight J (2003). "Treatments for spasticity and pain in multiple sclerosis: a systematic review". Health Technology Assessment. 7 (40): iii, ix–x, 1–111. doi:10.3310/hta7400. PMID 14636486.
Paisley S, Beard S, Hunn A, Wight J (August 2002). "Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review". Multiple Sclerosis. 8 (4): 319–329. doi:10.1191/1352458502ms795rr. PMID 12166503. S2CID 1641319.
Becker WJ, Harris CJ, Long ML, Ablett DP, Klein GM, DeForge DA (August 1995). "Long-term intrathecal baclofen therapy in patients with intractable spasticity". The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques. 22 (3): 208–217. doi:10.1017/S031716710003986X. PMID 8529173.
Asnafi S, Morris PP, Sechi E, Pittock SJ, Weinshenker BG, Palace J, et al. (January 2020). "The frequency of longitudinally extensive transverse myelitis in MS: A population-based study". Multiple Sclerosis and Related Disorders. 37: 101487. doi:10.1016/j.msard.2019.101487. PMID 31707235.
Koch M, Mostert J, Heersema D, De Keyser J (February 2007). "Tremor in multiple sclerosis". Journal of Neurology. 254 (2): 133–145. doi:10.1007/s00415-006-0296-7. PMC 1915650. PMID 17318714.
Bozek CB, Kastrukoff LF, Wright JM, Perry TL, Larsen TA (January 1987). "A controlled trial of isoniazid therapy for action tremor in multiple sclerosis". Journal of Neurology. 234 (1): 36–39. doi:10.1007/BF00314007. PMID 3546605. S2CID 23597601.
Duquette P, Pleines J, du Souich P (December 1985). "Isoniazid for tremor in multiple sclerosis: a controlled trial". Neurology. 35 (12): 1772–1775. doi:10.1212/wnl.35.12.1772. PMID 3906430. S2CID 24266989.
Hallett M, Lindsey JW, Adelstein BD, Riley PO (September 1985). "Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis". Neurology. 35 (9): 1374–1377. doi:10.1212/wnl.35.9.1374. PMID 3895037. S2CID 30254514.
Koller WC (March 1984). "Pharmacologic trials in the treatment of cerebellar tremor". Archives of Neurology. 41 (3): 280–281. doi:10.1001/archneur.1984.04050150058017. PMID 6365047.
Sechi GP, Zuddas M, Piredda M, Agnetti V, Sau G, Piras ML, et al. (August 1989). "Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up". Neurology. 39 (8): 1113–1115. doi:10.1212/wnl.39.8.1113. PMID 2668787. S2CID 36050520.
Aisen ML, Holzer M, Rosen M, Dietz M, McDowell F (May 1991). "Glutethimide treatment of disabling action tremor in patients with multiple sclerosis and traumatic brain injury". Archives of Neurology. 48 (5): 513–515. doi:10.1001/archneur.1991.00530170077023. PMID 2021365.
Mills RJ, Yap L, Young CA (January 2007). Mills RJ (ed.). "Treatment for ataxia in multiple sclerosis". The Cochrane Database of Systematic Reviews (1): CD005029. doi:10.1002/14651858.CD005029.pub2. PMID 17253537.
Aisen ML, Arnold A, Baiges I, Maxwell S, Rosen M (July 1993). "The effect of mechanical damping loads on disabling action tremor". Neurology. 43 (7): 1346–1350. doi:10.1212/wnl.43.7.1346. PMID 8327136. S2CID 23433712.
Bittar RG, Hyam J, Nandi D, Wang S, Liu X, Joint C, et al. (August 2005). "Thalamotomy versus thalamic stimulation for multiple sclerosis tremor". Journal of Clinical Neuroscience. 12 (6): 638–642. doi:10.1016/j.jocn.2004.09.008. PMID 16098758. S2CID 38770179.
Odintsova TA, Kopchak OO (2021). "Sleep Disorders in Relapsing-Remitting Multiple Sclerosis Patients" (PDF). Wiadomości Lekarskie. 74 (2): 257–262. doi:10.36740/WLek202102115. PMID 33813482.
Stanton BR, Barnes F, Silber E (2006). "Sleep and fatigue in multiple sclerosis". Multiple Sclerosis Journal. 12 (4): 481–486. doi:10.1191/135248506ms1320oa. PMID 16900762.
Laslett LL, Honan C, Turner JA, Dagnew B, Campbell JA, Gill TK, et al. (2022). "Poor sleep and multiple sclerosis: Associations with symptoms of multiple sclerosis and quality of life". Journal of Neurology, Neurosurgery & Psychiatry. 93 (11): 1162–1165. doi:10.1136/jnnp-2022-329227. PMID 35896381.
Patel KS, Dunn KM, Brown A, Opelt B, Hughes AJ, Hughes AJ (2023). "Sleep disturbance and fatigue in multiple sclerosis: A systematic review and meta-analysis". Multiple Sclerosis Journal - Experimental, Translational and Clinical. 9 (3). doi:10.1177/20552173231194352. PMC 10460472. PMID 37641617.
Strober LB (2015). "Fatigue in Multiple Sclerosis: A Look at the Role of Poor Sleep". Frontiers in Neurology. 6: 21. doi:10.3389/fneur.2015.00021. PMC 4325921. PMID 25729378.

ncbi.nlm.nih.gov

Hubbard AL, Golla H, Lausberg H (June 2021). "What's in a name? That which we call Multiple Sclerosis Fatigue". Multiple Sclerosis. 27 (7): 983–988. doi:10.1177/1352458520941481. PMC 8142120. PMID 32672087.
Bakalidou D, Giannopapas V, Giannopoulos S (July 2023). "Thoughts on Fatigue in Multiple Sclerosis Patients". Cureus. 15 (7): e42146. doi:10.7759/cureus.42146. PMC 10438195. PMID 37602098.
Tervonen T, Fox RJ, Brooks A, Sidorenko T, Boyanova N, Levitan B, et al. (2023). "Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment". Multiple Sclerosis Journal: Experimental, Translational and Clinical. 9 (1): 20552173221150370. doi:10.1177/20552173221150370. PMC 9880588. PMID 36714174.
Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, et al. (June 2019). "Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 90 (6): 642–651. doi:10.1136/jnnp-2018-320050. PMC 6581095. PMID 30683707.
Ellison PM, Goodall S, Kennedy N, Dawes H, Clark A, Pomeroy V, et al. (September 2022). "Neurostructural and Neurophysiological Correlates of Multiple Sclerosis Physical Fatigue: Systematic Review and Meta-Analysis of Cross-Sectional Studies". Neuropsychology Review. 32 (3): 506–519. doi:10.1007/s11065-021-09508-1. PMC 9381450. PMID 33961198.
Newland P, Starkweather A, Sorenson M (July 2016). "Central fatigue in multiple sclerosis: a review of the literature". The Journal of Spinal Cord Medicine. 39 (4): 386–399. doi:10.1080/10790268.2016.1168587. PMC 5102292. PMID 27146427.
Davis SL, Wilson TE, White AT, Frohman EM (November 2010). "Thermoregulation in multiple sclerosis". Journal of Applied Physiology. 109 (5): 1531–1537. doi:10.1152/japplphysiol.00460.2010. PMC 2980380. PMID 20671034.
Sumowski JF, Leavitt VM (July 2014). "Body temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure". Archives of Physical Medicine and Rehabilitation. 95 (7): 1298–1302. doi:10.1016/j.apmr.2014.02.004. PMC 4071126. PMID 24561056.
Loy BD, Taylor RL, Fling BW, Horak FB (September 2017). "Relationship between perceived fatigue and performance fatigability in people with multiple sclerosis: A systematic review and meta-analysis". Journal of Psychosomatic Research. 100: 1–7. doi:10.1016/j.jpsychores.2017.06.017. PMC 5875709. PMID 28789787.
Patejdl R, Zettl UK (2022). "The pathophysiology of motor fatigue and fatigability in multiple sclerosis". Frontiers in Neurology. 13: 891415. doi:10.3389/fneur.2022.891415. PMC 9363784. PMID 35968278.
Chalah MA, Riachi N, Ahdab R, Créange A, Lefaucheur JP, Ayache SS (2015). "Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation". Frontiers in Cellular Neuroscience. 9: 460. doi:10.3389/fncel.2015.00460. PMC 4663273. PMID 26648845.
Gerber LH, Weinstein AA, Mehta R, Younossi ZM (July 2019). "Importance of fatigue and its measurement in chronic liver disease". World Journal of Gastroenterology. 25 (28): 3669–3683. doi:10.3748/wjg.v25.i28.3669. PMC 6676553. PMID 31391765.
Camera V, Mariano R, Messina S, Menke R, Griffanti L, Craner M, et al. (2023). "Shared imaging markers of fatigue across multiple sclerosis, aquaporin-4 antibody neuromyelitis optica spectrum disorder and MOG antibody disease". Brain Communications. 5 (3): fcad107. doi:10.1093/braincomms/fcad107. PMC 10171455. PMID 37180990.
Novo AM, Batista S, Alves C, d'Almeida OC, Marques IB, Macário C, et al. (December 2018). "The neural basis of fatigue in multiple sclerosis: A multimodal MRI approach". Neurology. Clinical Practice. 8 (6): 492–500. doi:10.1212/CPJ.0000000000000545. PMC 6294533. PMID 30588379.
Muñoz Maniega S, Chappell FM, Valdés Hernández MC, Armitage PA, Makin SD, Heye AK, et al. (February 2017). "Integrity of normal-appearing white matter: Influence of age, visible lesion burden and hypertension in patients with small-vessel disease". Journal of Cerebral Blood Flow and Metabolism. 37 (2): 644–656. doi:10.1177/0271678X16635657. PMC 5381455. PMID 26933133.
"Fatigue in early multiple sclerosis: MRI metrics of neuroinflammation, relapse and neurodegeneration". Brain Communications. 6 (5): fcae278. October 1, 2024. doi:10.1093/braincomms/fcae278. PMC 11462441 – via Silverchair.
Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C (January 2007). Pucci E (ed.). "Amantadine for fatigue in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2007 (1): CD002818. doi:10.1002/14651858.CD002818.pub2. PMC 6991937. PMID 17253480.
Pinarello C, Elmers J, Inojosa H, Beste C, Ziemssen T (2023). "Management of multiple sclerosis fatigue in the digital age: from assessment to treatment". Frontiers in Neuroscience. 17: 1231321. doi:10.3389/fnins.2023.1231321. PMC 10585158. PMID 37869507.
Betts CD, D'Mellow MT, Fowler CJ (March 1993). "Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 56 (3): 245–250. doi:10.1136/jnnp.56.3.245. PMC 1014855. PMID 8459239.
The National Collaborating Centre for Chronic Conditions (UK) (2004). "Diagnosis and treatment of specific impairments". Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care (PDF). NICE Clinical Guidelines. Vol. 8. London: Royal College of Physicians (UK). pp. 87–132. ISBN 978-1-86016-182-7. PMID 21290636. Retrieved 6 February 2013.
Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. (2018). "Recommendations for cognitive screening and management in multiple sclerosis care". Multiple Sclerosis Journal. 24 (13): 1665–1680. doi:10.1177/1352458518803785. PMC 6238181. PMID 30303036.
Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, et al. (2018). "Cognition in multiple sclerosis". Neurology. 90 (6): 278–288. doi:10.1212/WNL.0000000000004977. PMC 5818015. PMID 29343470.
Achiron A, Barak Y (April 2003). "Cognitive impairment in probable multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 74 (4): 443–446. doi:10.1136/jnnp.74.4.443. PMC 1738365. PMID 12640060.
Kletenik I, Cohen AL, Glanz BI, Ferguson MA, Tauhid S, Li J, et al. (November 2023). "Multiple sclerosis lesions that impair memory map to a connected memory circuit". Journal of Neurology. 270 (11): 5211–5222. doi:10.1007/s00415-023-11907-8. PMC 10592111. PMID 37532802. S2CID 260433348.
Siegert RJ, Abernethy DA (April 2005). "Depression in multiple sclerosis: a review". Journal of Neurology, Neurosurgery, and Psychiatry. 76 (4): 469–475. doi:10.1136/jnnp.2004.054635. PMC 1739575. PMID 15774430.
Cervetto L, Demontis GC, Gargini C (February 2007). "Cellular mechanisms underlying the pharmacological induction of phosphenes". British Journal of Pharmacology. 150 (4): 383–390. doi:10.1038/sj.bjp.0706998. PMC 2189731. PMID 17211458.
"An intereye difference of 5–6 μm in RNFL thickness is a robust structural threshold for identifying the presence of a unilateral optic nerve lesion in MS." Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C, et al. (December 2018). "Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis". Journal of Neuro-Ophthalmology. 38 (4): 451–458. doi:10.1097/WNO.0000000000000629. PMC 8845082. PMID 29384802.
Jiang H, Delgado S, Wang J (February 2021). "Advances in ophthalmic structural and functional measures in multiple sclerosis: do the potential ocular biomarkers meet the unmet needs?". Current Opinion in Neurology. 34 (1): 97–107. doi:10.1097/WCO.0000000000000897. PMC 7856092. PMID 33278142.
Nij Bijvank J, Uitdehaag BM, Petzold A (February 2022). "Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics". Journal of Neurology, Neurosurgery, and Psychiatry. 93 (2): 216–219. doi:10.1136/jnnp-2021-327468. PMC 8785044. PMID 34764152.
Bsteh G, Hegen H, Altmann P, Auer M, Berek K, Pauli FD, et al. (October 19, 2020). "Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis". Multiple Sclerosis Journal: Experimental, Translational and Clinical. 6 (4): 2055217320966344. doi:10.1177/2055217320966344. PMC 7604994. PMID 33194221.
Kanchandani R, Howe JG (April 1982). "Lhermitte's sign in multiple sclerosis: a clinical survey and review of the literature". Journal of Neurology, Neurosurgery, and Psychiatry. 45 (4): 308–312. doi:10.1136/jnnp.45.4.308. PMC 491365. PMID 7077340.
Schmidt FA, Maas MB, Geran R, Schmidt C, Kunte H, Ruprecht K, et al. (July 2017). "Olfactory dysfunction in patients with primary progressive MS". Neurology. 4 (4): e369. doi:10.1212/NXI.0000000000000369. PMC 5471346. PMID 28638852. S2CID 1080966.
Lakhan SE, Rowland M (December 2009). "Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review". BMC Neurology. 9: 59. doi:10.1186/1471-2377-9-59. PMC 2793241. PMID 19961570.
Koch M, Mostert J, Heersema D, De Keyser J (February 2007). "Tremor in multiple sclerosis". Journal of Neurology. 254 (2): 133–145. doi:10.1007/s00415-006-0296-7. PMC 1915650. PMID 17318714.
Patel KS, Dunn KM, Brown A, Opelt B, Hughes AJ, Hughes AJ (2023). "Sleep disturbance and fatigue in multiple sclerosis: A systematic review and meta-analysis". Multiple Sclerosis Journal - Experimental, Translational and Clinical. 9 (3). doi:10.1177/20552173231194352. PMC 10460472. PMID 37641617.
Strober LB (2015). "Fatigue in Multiple Sclerosis: A Look at the Role of Poor Sleep". Frontiers in Neurology. 6: 21. doi:10.3389/fneur.2015.00021. PMC 4325921. PMID 25729378.

nlm.nih.gov

"Amantadine". Medline. US National Library of Medicine. April 2003. Retrieved 7 October 2007.
"Pemoline". Medline. US National Library of Medicine. January 2006. Retrieved 7 October 2007.
"Desmopressin". MedlinePlus. U.S. National Library of Medicine.
"Baclofen oral". Medline. U.S. National Library of Medicine. April 2003. Retrieved 17 October 2007.
"Dantrolene oral". Medline. U.S. National Library of Medicine. April 2003. Retrieved 17 October 2007.
"Diazepam". Medline. U.S. National Library of Medicine. April 2003. Retrieved 17 October 2007.
"Tizanidine". Medline. U.S. National Library of Medicine. April 2003. Retrieved 17 October 2007..
"Isoniazid". Medline. U.S. National Library of Medicine. April 2003. Retrieved 17 October 2007.

oup.com

academic.oup.com

"Fatigue in early multiple sclerosis: MRI metrics of neuroinflammation, relapse and neurodegeneration". Brain Communications. 6 (5): fcae278. October 1, 2024. doi:10.1093/braincomms/fcae278. PMC 11462441 – via Silverchair.

pcori.org

"Comparing Treatments for Multiple Sclerosis-Related Fatigue - Evidence Update for Clinicians | PCORI". www.pcori.org. 2023-09-01. Retrieved 2023-11-30.

practicalneurology.com

"Fatigue in Patients With Multiple Sclerosis". Practical Neurology.
"Fatigue in Patients with Multiple Sclerosis".

psu.edu

citeseerx.ist.psu.edu

Mohr DC, Hart SL, Goldberg A (2003). "Effects of treatment for depression on fatigue in multiple sclerosis". Psychosomatic Medicine. 65 (4): 542–547. CiteSeerX 10.1.1.318.5928. doi:10.1097/01.PSY.0000074757.11682.96. PMID 12883103. S2CID 16239318.
Patten SB, Beck CA, Williams JV, Barbui C, Metz LM (December 2003). "Major depression in multiple sclerosis: a population-based perspective". Neurology. 61 (11): 1524–1527. CiteSeerX 10.1.1.581.3646. doi:10.1212/01.wnl.0000095964.34294.b4. PMID 14663036. S2CID 1602489.

rcplondon.ac.uk

The Royal College of Physicians (2004). Multiple Sclerosis. National clinical guideline for diagnosis and management in primary and secondary care (PDF). Salisbury, Wiltshire: Sarum ColourView Group. ISBN 978-1-86016-182-7.

researchgate.net

Stanton BR, Barnes F, Silber E (2006). "Sleep and fatigue in multiple sclerosis". Multiple Sclerosis Journal. 12 (4): 481–486. doi:10.1191/135248506ms1320oa. PMID 16900762.

semanticscholar.org

api.semanticscholar.org

Jongen PJ (June 2006). "Psychiatric onset of multiple sclerosis". Journal of the Neurological Sciences. 245 (1–2): 59–62. doi:10.1016/j.jns.2005.09.014. PMID 16631798. S2CID 33098365.
Paty D, Studney D, Redekop K, Lublin F (1994). "MS COSTAR: a computerized patient record adapted for clinical research purposes". Annals of Neurology. 36 (Suppl): S134 – S135. doi:10.1002/ana.410360732. PMID 8017875. S2CID 23425667.
Hartvig Honoré P (June 2013). "Fatigue". European Journal of Hospital Pharmacy. 20 (3): 147–148. doi:10.1136/ejhpharm-2013-000309. S2CID 220171226.
Bakshi R (June 2003). "Fatigue associated with multiple sclerosis: diagnosis, impact and management". Multiple Sclerosis. 9 (3): 219–227. doi:10.1191/1352458503ms904oa. PMID 12814166. S2CID 40931716.
Mohr DC, Hart SL, Goldberg A (2003). "Effects of treatment for depression on fatigue in multiple sclerosis". Psychosomatic Medicine. 65 (4): 542–547. CiteSeerX 10.1.1.318.5928. doi:10.1097/01.PSY.0000074757.11682.96. PMID 12883103. S2CID 16239318.
Sepulcre J, Masdeu JC, Goñi J, Arrondo G, Vélez de Mendizábal N, Bejarano B, et al. (March 2009). "Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways". Multiple Sclerosis. 15 (3): 337–344. doi:10.1177/1352458508098373. PMID 18987107. S2CID 2701289.
Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP (August 1992). "A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis". Neurology. 42 (8): 1468–1471. doi:10.1212/wnl.42.8.1468. PMID 1641137. S2CID 41990406.
Mathiowetz VG, Finlayson ML, Matuska KM, Chen HY, Luo P (October 2005). "Randomized controlled trial of an energy conservation course for persons with multiple sclerosis". Multiple Sclerosis. 11 (5): 592–601. doi:10.1191/1352458505ms1198oa. PMID 16193899. S2CID 33902095.
Hennessey A, Robertson NP, Swingler R, Compston DA (November 1999). "Urinary, faecal and sexual dysfunction in patients with multiple sclerosis". Journal of Neurology. 246 (11): 1027–1032. doi:10.1007/s004150050508. PMID 10631634. S2CID 30179761.
Bosma R, Wynia K, Havlíková E, De Keyser J, Middel B (July 2005). "Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis". Acta Neurologica Scandinavica. 112 (1): 1–5. doi:10.1111/j.1600-0404.2005.00431.x. hdl:11370/1eb88003-4dfb-4de1-9aa2-1100972e8666. PMID 15932348. S2CID 46673620.
DasGupta R, Fowler CJ (2003). "Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies". Drugs. 63 (2): 153–166. doi:10.2165/00003495-200363020-00003. PMID 12515563. S2CID 46351374.
Rao SM, Leo GJ, Bernardin L, Unverzagt F (May 1991). "Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction". Neurology. 41 (5): 685–691. doi:10.1212/wnl.41.5.685. PMID 2027484. S2CID 9962959.
Dujardin K, Donze AC, Hautecoeur P (January 1998). "Attention impairment in recently diagnosed multiple sclerosis". European Journal of Neurology. 5 (1): 61–66. doi:10.1046/j.1468-1331.1998.510061.x. PMID 10210813. S2CID 33389996.
Kletenik I, Cohen AL, Glanz BI, Ferguson MA, Tauhid S, Li J, et al. (November 2023). "Multiple sclerosis lesions that impair memory map to a connected memory circuit". Journal of Neurology. 270 (11): 5211–5222. doi:10.1007/s00415-023-11907-8. PMC 10592111. PMID 37532802. S2CID 260433348.
Chiaravalloti ND, DeLuca J (December 2008). "Cognitive impairment in multiple sclerosis". The Lancet. Neurology. 7 (12): 1139–1151. doi:10.1016/S1474-4422(08)70259-X. PMID 19007738. S2CID 25783642.
Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, et al. (March 1996). "Depression and multiple sclerosis". Neurology. 46 (3): 628–632. doi:10.1212/wnl.46.3.628. PMID 8618657. S2CID 33587300.
Patten SB, Beck CA, Williams JV, Barbui C, Metz LM (December 2003). "Major depression in multiple sclerosis: a population-based perspective". Neurology. 61 (11): 1524–1527. CiteSeerX 10.1.1.581.3646. doi:10.1212/01.wnl.0000095964.34294.b4. PMID 14663036. S2CID 1602489.
Sadovnick AD, Eisen K, Ebers GC, Paty DW (August 1991). "Cause of death in patients attending multiple sclerosis clinics". Neurology. 41 (8): 1193–1196. doi:10.1212/wnl.41.8.1193. PMID 1866003. S2CID 31905744.
Leigh RJ, Averbuch-Heller L, Tomsak RL, Remler BF, Yaniglos SS, Dell'Osso LF (August 1994). "Treatment of abnormal eye movements that impair vision: strategies based on current concepts of physiology and pharmacology". Annals of Neurology. 36 (2): 129–141. doi:10.1002/ana.410360204. PMID 8053648. S2CID 23670958.
Starck M, Albrecht H, Pöllmann W, Straube A, Dieterich M (January 1997). "Drug therapy for acquired pendular nystagmus in multiple sclerosis". Journal of Neurology. 244 (1): 9–16. doi:10.1007/PL00007728. PMID 9007739. S2CID 12333107.
Freeman JA (April 2001). "Improving mobility and functional independence in persons with multiple sclerosis". Journal of Neurology. 248 (4): 255–259. doi:10.1007/s004150170198. PMID 11374088. S2CID 12461962.
Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, et al. (May 2013). "Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis". Pain. 154 (5): 632–642. doi:10.1016/j.pain.2012.12.002. PMID 23318126. S2CID 25807525.
Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, et al. (July 1994). "Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients". Pain. 58 (1): 89–93. doi:10.1016/0304-3959(94)90188-0. PMID 7970843. S2CID 25295712.
Solaro C, Messmer Uccelli M, Uccelli A, Leandri M, Mancardi GL (2000). "Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis". European Neurology. 44 (1): 45–48. doi:10.1159/000008192. hdl:11567/301010. PMID 10894995. S2CID 39508538.
Athanasiou TC, Patel NK, Renowden SA, Coakham HB (December 2005). "Some patients with multiple sclerosis have neurovascular compression causing their trigeminal neuralgia and can be treated effectively with MVD: report of five cases". British Journal of Neurosurgery. 19 (6): 463–468. doi:10.1080/02688690500495067. PMID 16574557. S2CID 33819410.
Eldridge PR, Sinha AK, Javadpour M, Littlechild P, Varma TR (2003). "Microvascular decompression for trigeminal neuralgia in patients with multiple sclerosis". Stereotactic and Functional Neurosurgery. 81 (1–4): 57–64. doi:10.1159/000075105. PMID 14742965. S2CID 39449873.
Al-Araji AH, Oger J (August 2005). "Reappraisal of Lhermitte's sign in multiple sclerosis". Multiple Sclerosis. 11 (4): 398–402. doi:10.1191/1352458505ms1177oa. PMID 16042221. S2CID 33610136.
Moulin DE, Foley KM, Ebers GC (December 1988). "Pain syndromes in multiple sclerosis". Neurology. 38 (12): 1830–1834. doi:10.1212/wnl.38.12.1830. PMID 2973568. S2CID 647138.
Schmidt FA, Maas MB, Geran R, Schmidt C, Kunte H, Ruprecht K, et al. (July 2017). "Olfactory dysfunction in patients with primary progressive MS". Neurology. 4 (4): e369. doi:10.1212/NXI.0000000000000369. PMC 5471346. PMID 28638852. S2CID 1080966.
Paisley S, Beard S, Hunn A, Wight J (August 2002). "Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review". Multiple Sclerosis. 8 (4): 319–329. doi:10.1191/1352458502ms795rr. PMID 12166503. S2CID 1641319.
Bozek CB, Kastrukoff LF, Wright JM, Perry TL, Larsen TA (January 1987). "A controlled trial of isoniazid therapy for action tremor in multiple sclerosis". Journal of Neurology. 234 (1): 36–39. doi:10.1007/BF00314007. PMID 3546605. S2CID 23597601.
Duquette P, Pleines J, du Souich P (December 1985). "Isoniazid for tremor in multiple sclerosis: a controlled trial". Neurology. 35 (12): 1772–1775. doi:10.1212/wnl.35.12.1772. PMID 3906430. S2CID 24266989.
Hallett M, Lindsey JW, Adelstein BD, Riley PO (September 1985). "Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis". Neurology. 35 (9): 1374–1377. doi:10.1212/wnl.35.9.1374. PMID 3895037. S2CID 30254514.
Sechi GP, Zuddas M, Piredda M, Agnetti V, Sau G, Piras ML, et al. (August 1989). "Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up". Neurology. 39 (8): 1113–1115. doi:10.1212/wnl.39.8.1113. PMID 2668787. S2CID 36050520.
Aisen ML, Arnold A, Baiges I, Maxwell S, Rosen M (July 1993). "The effect of mechanical damping loads on disabling action tremor". Neurology. 43 (7): 1346–1350. doi:10.1212/wnl.43.7.1346. PMID 8327136. S2CID 23433712.
Bittar RG, Hyam J, Nandi D, Wang S, Liu X, Joint C, et al. (August 2005). "Thalamotomy versus thalamic stimulation for multiple sclerosis tremor". Journal of Clinical Neuroscience. 12 (6): 638–642. doi:10.1016/j.jocn.2004.09.008. PMID 16098758. S2CID 38770179.

ucl.ac.uk

discovery.ucl.ac.uk

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, et al. (May 2016). "Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study". The Lancet. Neurology. 15 (6): 574–584. doi:10.1016/S1474-4422(16)00068-5. PMID 27011339.

va.gov

"VA.gov | Veterans Affairs". www.va.gov.

web.archive.org

"Heat Sensitivity". Archived from the original on 2024-01-17. Retrieved 2024-03-15.
Trust MS. "Temperature sensitivity | MS Trust". mstrust.org.uk. Archived from the original on 2024-01-17. Retrieved 2024-03-15.
"Temperature sensitivity". mstrust.org.uk. Archived from the original on 2024-01-17. Retrieved 2024-03-15.

webmd.com

Richard Senelick (Reviewer) (Aug 2012). "The Speech and Swallowing Problems of Multiple Sclerosis". Web MD. Retrieved 25 May 2013.

wiadlek.pl

Odintsova TA, Kopchak OO (2021). "Sleep Disorders in Relapsing-Remitting Multiple Sclerosis Patients" (PDF). Wiadomości Lekarskie. 74 (2): 257–262. doi:10.36740/WLek202102115. PMID 33813482.

ymaws.com

cdn.ymaws.com

O'Leary M, Heyman R, Erickson J, Chancellor MB (June 2007). Premature Ejaculation and MS: A Review (PDF) (Report). Consortium of MS Centers.